# A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

> **NCT02587715** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Novo Cellular Medicine Institute LLP** · enrollment: 69 (estimated)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells
- **OTHER:** Liberation therapy

## Key facts

- **NCT ID:** NCT02587715
- **Lead sponsor:** Novo Cellular Medicine Institute LLP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02587715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02587715, "A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02587715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*